MoonLake Immunotherapeutics(US:MLTX) Globenewswire·2025-10-08 14:15Core Viewpoint - MoonLake Immunotherapeutics experienced a significant decline in its stock price, dropping over 80% following disappointing results from two late-stage trials of its drug sonelokimab for hidradenitis suppurativa, raising concerns about the drug's regulatory and commercial viability [4]. Group 1: Company Overview - MoonLake Immunotherapeutics is under investigation by Faruqi & Faruqi, LLP, a national securities law firm, for potential claims related to the significant losses suffered by investors [3]. - The firm has a history of recovering hundreds of millions of dollars for investors since its establishment in 1995 [3]. Group 2: Trial Results - The first late-stage trial of sonelokimab showed a statistically significant improvement over placebo, but the benefit margin did not meet investor expectations [4]. - The second trial failed to meet its primary endpoint, attributed to an unexpectedly high placebo response, leading to skepticism regarding the drug's future [4]. Group 3: Market Reaction - The disappointing trial results prompted a sharp sell-off in MoonLake's stock, reflecting analysts' doubts about the drug's regulatory path and commercial potential [4].